EXCLUSIVE: NeuroSense Therapeutics Tells Benzinga Co. Reports That It Is Currently In Advanced Discussions With Several Multi-Billion-Dollar Pharmaceutical Companies Regarding A Potential Strategic Partnership For The Development And Commercialization...
EXCLUSIVE: NeuroSense Therapeutics Tells Benzinga Co. Reports That It Is Currently In Advanced Discussions With Several Multi-Billion-Dollar Pharmaceutical Companies Regarding A Potential Strategic Partnership For The Development And Commercialization...
獨家消息:NeuroSense Therapeutics告訴Benzinga公司,目前正在與幾家市值數十億美元的醫藥公司進行高級討論,就發展和商業化的潛在戰略合作伙伴關係達成一致...
EXCLUSIVE: NeuroSense Therapeutics Tells Benzinga Co. Reports That It Is Currently In Advanced Discussions With Several Multi-Billion-Dollar Pharmaceutical Companies Regarding A Potential Strategic Partnership For The Development And Commercialization Of Its Lead Drug Candidate, PrimeC, For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
獨家:NeuroSense Therapeutics告訴Benzinga公司,它目前正在與幾家價值數十億美元的藥品公司進行深入討論,就旗下主力藥物候選PrimeC治療肌萎縮側索硬化症(ALS)的開發和商業化潛在戰略合作。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。